Logo

Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

Share this
Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

Shots:

  • The P-III SURPASS-CVOT study involves assessing non-inferiority and superiority of tirzepatide vs Trulicity (dulaglutide- 15mg) in 12-500 patients with T2D and atherosclerotic cardiovascular disease from 30 countries. The company expects for the completion of trial in four years
  • The 1EPs will measure time to first occurrence of MACE-3- the composite endpoint of CV death- myocardial infarction- or stroke while the 2EPs is time to all-cause mortality and time to occurrence of each component of the primary endpoint
  • Trulicity (dulaglutide) is an injectable prescribed medicine for T2D patients used to improve blood sugar (glucose) and used to reduce the risk of major cardiovascular events such as death- heart attack- or stroke in people who have heart disease or multiple cardiovascular risk factors

Click here to read full press release/ article 

 Ref: PRNewswire | Image: Eli Lilly 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions